?? 南京永信贵宾会生物科技有限公司

永信贵宾会

中

北必达，恒致远

Determination?Guarantees?Success,?Perserverance?Makes?Perfection

Bioheng had secured?$80 million?in Series B Financing. The Series B was co-led by GL Ventures, Decheng Capital and Octagon Capital, with the participation of?BRV China?and SCGC.

More  ?

UCART
As a new type of fifth-generation immunotherapy product, CART has incomparable advantages such as industrialized production, stable quality, low cost, more patients and short cycle. It is the only way and inevitable trend of future immunotherapy technology.
More  ?

UCART

About Us

About Us

BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on?novel immunotherapy and?next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus...

More 

Immunotherapy

Immunotherapy

Gene Therapy

Gene Therapy

CRO Service

CRO Service

News and Updates
Company Updates Recent News

China CDE Approved First Universal CAR-T IND !

OnMarch17,2022,ChinaNationalDrugAdminist……

more

CTB001, Bioheng auto CAR - T Product, received Orphan Drug Designation (ODD) from the U.S. FDA

Recently,NanjingBiohengBiotechCo.,Ltd(he……

more

Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL.

NanjingBiohengBiotechCo.,Ltd. Annou……

more

More

Nanjing Bioheng Biotech Co., Ltd.

  • Address :

    Block B1-2, 73 Tanmi Road, Pukou District, Nanjing, China

  • Hotline :

    Telephone :

    400-828-8076

    025-85590456

  • Email :

    service@sh-tnp.com

Follow our wechat account

Follow Our Wechat Account

Copyright Nanjing Bioheng Biotech Co., Ltd.@ 2018 China All Rights Reserved